Olaparib
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07641855CT.gov A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07090369CT.gov Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT06353386CT.gov Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | — | Recruiting | — | — | — |
NCT05807126CT.gov Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | — | Withdrawn | — | — | — |
NCT05501548CT.gov Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT06783127CT.gov Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04951492CT.gov Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | — | Terminated | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04038502CT.gov Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | — | Recruiting | — | — | — |
Show 5 more trialsShow fewer
NCT03874884CT.gov 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03317392CT.gov Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | — | Active Not Recruiting | — | — | — |
NCT03516812CT.gov Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02893917CT.gov Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03012321CT.gov Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | AstraZeneca | P2/3 | BB · 64 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Abiraterone | AstraZeneca | P4 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-castration-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →